A Newly Approved Alkyne: Covalent FGFR1-4 Kinase Inhibitor, Futibatinib

Futibatinib (Lytgobi) is a rare alkyne-containing, irreversible FGFR1-4 inhibitor that received accelerated approval from the FDA in September 2022. Structurally distinct from other approved FGFR2/3 inhibitors, futibatinib treats a range of FGFR-aberrant tumors, including those with fusions or TKI-resistant mutants like the V565I/L gatekeeper mutation.

This Premium report reviews:

  • the role of FGFR mutations in oncogenesis and drug resistance
  • differences between approved and emerging FGFR inhibitors
  • human data on futibatinib, including PK and efficacy

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!